NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Niva Bupa Health Insurance Company Ltd., formerly Max Bupa Health Insurance Company, will launch its initial public offering tomorrow and the offer closes for subscription on Nov. 11. India's prominent health insurance provider has fixed a price band of Rs 70-74 per share for its Rs 2,200 crore initial share sale. The minimum order lot for booking is 200.
The IPO is a combination of fresh issuance of equity shares worth Rs 800 crore and an offer for sale of up to Rs 1,400 crore by promoters.
Object of the issue
Augmentation of the Company’s capital base to maintain and strengthen their solvency ratio.
Valuation & outlook
Niva Bupa Health Insurance Company is a prominent health insurance provider in India. As of Q1 FY25, the company insured 14.99 million active lives. With a strategic emphasis on the retail health market, their Gross Written Premium from retail health products accounted for 67.65% and 68.47% of their total GWP for Q1 FY25, and for Fiscal 2024, respectively.
They offer a diverse range of products for customers, strengthened by a strong track record in product innovation. Their health insurance offerings are designed to meet the needs of customers at every stage of life. The company aims to build a comprehensive, customer-focused health insurance platform and healthcare ecosystem, offering customers access to a variety of services, including wellness programs, doctor consultations, diagnostics, and medicine delivery.
They plan to keep investing in developing and expanding their health insurance ecosystem through their own initiatives, like introducing more health assessment tools and wellness content, and by partnering strategically for services such as digital consultations and home medicine delivery.
At the upper price band company is valued at P/BV of 6.1X with a market cap of Rs 1,35,200 million post issue of equity shares. We believe that the issue is fully priced and recommend “Subscribe – Long Term” rating to the IPO.
Click on the attachment to read the full IPO report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.